ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – PatientCase Follow-Up
Pulmonology
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier revisits a patientcase study where a biologic has been added to an asthma management plan and describes the potential for this patient to achieve on-therapy clinical remission.
ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?
Pulmonology
Professor Klaus Rabe shares a patientcase highlighting the burden of disease associated with airway remodeling and discusses practical aspects of identifying and managing airway remodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.
Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
An interactive guide that provides users with an overview of key assessment tools for Prurigo Nodularis clinical practice. Implementation of the most applied tools is exemplified via a patientcase.
An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.